These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35155433)

  • 1. Crosstalk Between Four Types of RNA Modification Writers Characterizes the Tumor Immune Microenvironment Infiltration Patterns in Skin Cutaneous Melanoma.
    Zhang S; Xiong Y; Zheng C; Long J; Zhou H; Zeng Z; Ouyang Y; Tang F
    Front Cell Dev Biol; 2022; 10():821678. PubMed ID: 35155433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer.
    Chen H; Yao J; Bao R; Dong Y; Zhang T; Du Y; Wang G; Ni D; Xun Z; Niu X; Ye Y; Li HB
    Mol Cancer; 2021 Feb; 20(1):29. PubMed ID: 33557837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Landscape of the Tumor Microenvironment in Skin Cutaneous Melanoma Reveals a Prognostic and Immunotherapeutically Relevant Gene Signature.
    Zhou S; Sun Y; Chen T; Wang J; He J; Lyu J; Shen Y; Chen X; Yang R
    Front Cell Dev Biol; 2021; 9():739594. PubMed ID: 34660598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA modification writers influence tumor microenvironment in gastric cancer and prospects of targeted drug therapy.
    Song P; Zhou S; Qi X; Jiao Y; Gong Y; Zhao J; Yang H; Qian Z; Qian J; Tang L
    J Bioinform Comput Biol; 2022 Apr; 20(2):2250004. PubMed ID: 35287562
    [No Abstract]   [Full Text] [Related]  

  • 5. Crosstalk of RNA Adenosine Modification-Related Subtypes, Establishment of a Prognostic Model, and Immune Infiltration Characteristics in Ovarian Cancer.
    Ni X; Chen C; Cui G; Ding W; Liu J
    Front Immunol; 2022; 13():932876. PubMed ID: 35837397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA modification writer expression profiles predict clinical outcomes and guide neoadjuvant immunotherapy in non-small cell lung cancer.
    Zhou B; Bie F; Zang R; Zhang M; Song P; Liu L; Peng Y; Bai G; Zhao J; Gao S
    EBioMedicine; 2022 Oct; 84():104268. PubMed ID: 36116215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated investigation of the clinical implications and targeted landscape for RNA methylation modifications in hepatocellular carcinoma.
    Zhang J; Gao J; Hu M; Xu S; Cheng C; Zheng W; Zhang J
    Eur J Med Res; 2023 Jan; 28(1):46. PubMed ID: 36707911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. m
    Chong W; Shang L; Liu J; Fang Z; Du F; Wu H; Liu Y; Wang Z; Chen Y; Jia S; Chen L; Li L; Chen H
    Theranostics; 2021; 11(5):2201-2217. PubMed ID: 33500720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. m
    Zhang B; Wu Q; Li B; Wang D; Wang L; Zhou YL
    Mol Cancer; 2020 Mar; 19(1):53. PubMed ID: 32164750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA M6A modification shaping cutaneous melanoma tumor microenvironment and predicting immunotherapy response.
    Wu Y; He H; Zheng K; Qin Z; Cai N; Zuo S; Zhu X
    Pigment Cell Melanoma Res; 2024 Jul; 37(4):496-509. PubMed ID: 38624045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.
    Meijing Z; Tianhang L; Biao Y
    Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification of m
    Du F; Li H; Li Y; Liu Y; Li X; Dang N; Chu Q; Yan J; Fang Z; Wu H; Zhang Z; Zhu X; Li X
    Front Cell Dev Biol; 2021; 9():761134. PubMed ID: 34993195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of anoikis-related subtypes and development of risk stratification system in skin cutaneous melanoma.
    Tian J; Cao ZJ; Zhang Y; Zhou JK; Yang L
    Heliyon; 2023 May; 9(5):e16153. PubMed ID: 37215879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA modification "writer"-mediated RNA modification patterns and tumor microenvironment characteristics of cervical cancer.
    Qu Y; Zhu H; Kong C; Zheng X; Wang D; Chen X; Yuan D
    Clin Transl Oncol; 2022 Jul; 24(7):1413-1424. PubMed ID: 35220552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel scoring model based on RNA modification "writers" can predict the prognosis and guide immunotherapy in gastric cancer.
    Li X; Zhou Y; Jiang Q; Huang J; Liu Z; Li Y; Guo G
    Funct Integr Genomics; 2023 May; 23(2):162. PubMed ID: 37188931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Identification of Two RNA Modification Patterns and Tumor Microenvironment Infiltration Characterization of Lung Adenocarcinoma.
    He W; Lin G; Pan C; Li W; Shen J; Liu Y; Li H; Wu D; Lin X
    Front Genet; 2022; 13():761681. PubMed ID: 35154267
    [No Abstract]   [Full Text] [Related]  

  • 17. m
    Sun M; Xie M; Zhang T; Wang Y; Huang W; Xia L
    Front Immunol; 2021; 12():739768. PubMed ID: 34616403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling cross-talk of RNA modification enzymes reveals tumor microenvironment-associated clinical significance and immunotherapy prediction in hepatobiliary malignancy.
    Qi F; Li J; Qi Z; Zhou B; Yang B; Zhang J; Qin W
    MedComm (2020); 2023 Jun; 4(3):e256. PubMed ID: 37090117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-talk of RNA modification "writers" describes tumor stemness and microenvironment and guides personalized immunotherapy for gastric cancer.
    Li Z; Zhang X; Weng W; Zhang G; Ren Q; Tian Y
    Aging (Albany NY); 2023 Jun; 15(12):5445-5481. PubMed ID: 37319315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. M6A Classification Combined With Tumor Microenvironment Immune Characteristics Analysis of Bladder Cancer.
    Zhu H; Jia X; Wang Y; Song Z; Wang N; Yang Y; Shi X
    Front Oncol; 2021; 11():714267. PubMed ID: 34604051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.